These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12021536)

  • 1. Evaluation of valaciclovir dosage reduction in continuous ambulatory peritoneal dialysis patients.
    Stathoulopoulou F; Dhillon S; Thodis H; Stathakis C; Vargemezis V
    Nephron; 2002 May; 91(1):164-6. PubMed ID: 12021536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections.
    Perry CM; Faulds D
    Drugs; 1996 Nov; 52(5):754-72. PubMed ID: 9118821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis.
    Stathoulopoulou F; Almond MK; Dhillon S; Raftery MJ
    Nephron; 1996; 74(2):337-41. PubMed ID: 8893152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness.
    Simon MW; Fish DN; Deeter RG
    Drugs R D; 2002; 3(6):365-73. PubMed ID: 12516939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.
    Izzedine H; Mercadal L; Aymard G; Launay-Vacher V; Martinez V; Issad B; Deray G
    Am J Nephrol; 2001; 21(2):162-4. PubMed ID: 11359026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.
    Soul-Lawton J; Seaber E; On N; Wootton R; Rolan P; Posner J
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2759-64. PubMed ID: 8593015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster.
    Lin WR; Lin HH; Lee SS; Tsai HC; Huang CK; Wann SR; Chen YS; Chiang SC; Yen MY; Liu YC
    J Microbiol Immunol Infect; 2001 Jun; 34(2):138-42. PubMed ID: 11456360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug clinics. How I treat zona].
    Nikkels AF; Piérard GE
    Rev Med Liege; 1999 Feb; 54(2):71-5. PubMed ID: 10221057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risk of CNS adverse effects of aciclovir and valaciclovir. Watch the renal function in treatment of herpes simplex and herpes zoster].
    Helldén A; Bergman U; Dwyer R; Medin C; Molanaei H; Ståhle L; Thylén P; Odar-Cederlöf I
    Lakartidningen; 2007 Jun 13-26; 104(24-25):1916-20. PubMed ID: 17674672
    [No Abstract]   [Full Text] [Related]  

  • 10. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults.
    Beutner KR; Friedman DJ; Forszpaniak C; Andersen PL; Wood MJ
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1546-53. PubMed ID: 7492102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensification of peritoneal dialysis improves valacyclovir neurotoxicity.
    Pipili C; Pantelias K; Deda E; Tsiamalos P; Kostis E; Grapsa E
    Ren Fail; 2013; 35(2):289-90. PubMed ID: 23176110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aciclovir and its l-valyl ester, valaciclovir.
    Smiley ML; Murray A
    Curr Probl Dermatol; 1996; 24():209-18. PubMed ID: 8743272
    [No Abstract]   [Full Text] [Related]  

  • 13. A retrospective study on the clinical outcome of herpes zoster in patients treated with acyclovir or valaciclovir vs. patients not treated with antiviral.
    Goh CL; Khoo L
    Int J Dermatol; 1998 Jul; 37(7):544-6. PubMed ID: 9679698
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.
    Weller S; Blum MR; Doucette M; Burnette T; Cederberg DM; de Miranda P; Smiley ML
    Clin Pharmacol Ther; 1993 Dec; 54(6):595-605. PubMed ID: 8275615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.
    Wang LH; Schultz M; Weller S; Smiley ML; Blum MR
    Antimicrob Agents Chemother; 1996 Jan; 40(1):80-5. PubMed ID: 8787884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotoxicity associated with acyclovir in end stage renal failure.
    Kitching AR; Fagg D; Hay NM; Hatfield PJ; Macdonald A
    N Z Med J; 1997 May; 110(1043):167-9. PubMed ID: 9196501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valaciclovir (BW256U87): the L-valyl ester of acyclovir.
    Jacobson MA
    J Med Virol; 1993; Suppl 1():150-3. PubMed ID: 8245883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valacyclovir neurotoxicity in a patient with end-stage renal disease treated with continuous ambulatory peritoneal dialysis.
    Okada T; Nakao T; Matsumoto H; Nagaoka Y; Iwasawa H; Nanri K; Yamazaki T
    Clin Nephrol; 2002 Aug; 58(2):168-70. PubMed ID: 12227692
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease.
    Jacobson MA; Gallant J; Wang LH; Coakley D; Weller S; Gary D; Squires L; Smiley ML; Blum MR; Feinberg J
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1534-40. PubMed ID: 7979285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dosage of oral valaciclovir as an alternative treatment of varicella zoster acute retinal necrosis syndrome.
    Guex-Crosier Y; Meylan PR
    Eye (Lond); 2006 Feb; 20(2):247. PubMed ID: 15776013
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.